Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23779954 | 0.97 | TDP1 (0.39) | TDP1CYP3A4TSHRESR1ESR2 | |
| SCHEMBL9518542 | 0.97 | TDP1 (0.39) | TDP1CYP3A4TSHRESR1ESR2 | |
| SCHEMBL684881 | 0.85 | TDP1 (0.38) | TDP1CYP3A4TSHRESR1ESR2 | |
| Ethylene Glycol SCHEMBL7950018 | 0.85 | TDP1 (0.38) | TDP1CYP3A4TSHRESR1ESR2 | |
| SCHEMBL11343369 | 0.83 | TDP1 (0.36) | TDP1CYP3A4TSHRESR1ESR2 | |
| SCHEMBL27343 | 0.83 | CYP3A4 (0.50) | TDP1CYP3A4TSHRESR1ESR2 | |
| SCHEMBL11343073 | 0.81 | KCNH3 (0.35) | TDP1CYP3A4TSHRESR1ESR2 | |
| SCHEMBL11336836 | 0.81 | KCNH3 (0.35) | TDP1CYP3A4TSHRESR1ESR2 | |
| SCHEMBL11336348 | 0.81 | KCNH3 (0.35) | TDP1CYP3A4TSHRESR1ESR2 | |
| SCHEMBL11333065 | 0.81 | KCNH3 (0.35) | TDP1CYP3A4TSHRESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102388014-A | Synthesis method of chiral alpha-aryl propionic acid derivative | DSM IP ASSETS BV | 2012-03-21 | — | — | CN | claimed |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | claimed |
| EP-2393771-A1 | Method for the synthesis of chiral alpha-aryl propionic acid derivatives | DSM IP Assets B.V. (NL) | 2011-12-14 | — | — | EP | claimed |
| WO-2010089343-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-08-12 | — | — | WO | claimed |
| CN-1686972-A | Cross couple method for synthesizing compound of liquid crystal from 2-2 phenyl phosphine ethanol through palladium catalysis | UNIV DALIAN TECH (CN) | 2005-10-26 | — | — | CN | claimed |
| EP-0327743-B1 | PROCEDURE FOR MANUFACTURING SHORT-CHAIN LINEAR ALPHA- OLEFINES FROM ETHYLENE | NESTE OY (FI) | 1993-01-20 | — | — | EP | claimed |
| EP-0327743-A1 | Procedure for manufacturing short-chain linear alpha- olefines from ethylene | NESTE OY (FI) | 1989-08-16 | — | — | EP | claimed |
| US-4816610-A | CATALYTIC DIMERIZATION | NESTE OY (FI) | 1989-03-28 | — | — | US | claimed |
| US-12110307-B2 | Self-immolative systems | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2024-10-08 | — | — | US | disclosed |
| CN-117720472-A | Benzimidazole compound, and preparation method and application thereof | 苏州沪云新药研发股份有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20210340166-A1 | SELF-IMMOLATIVE SYSTEMS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2021-11-04 | — | — | US | disclosed |
| EP-3873914-A1 | SELF-IMMOLATIVE SYSTEMS | The Secretary of State for Defence (GB) | 2021-09-08 | — | — | EP | disclosed |
| EP-3766981-A1 | CATIONIC POLOXAMERS AND THEIR USE IN TRANSDUCTION | OZ Biosciences (FR) | 2021-01-20 | — | — | EP | disclosed |
| CN-103664898-B | Organo-metallic compound and organic light emitting apparatus comprising it | 三星显示有限公司 | 2019-03-12 | — | — | CN | disclosed |
| WO-1998025939-A1 | CIS-BRIDGED METAL COMPLEXES | BASF AKTIENGESELLSCHAFT (DE) | 1998-06-18 | — | — | WO | disclosed |
| EP-0327743-B1 | PROCEDURE FOR MANUFACTURING SHORT-CHAIN LINEAR ALPHA- OLEFINES FROM ETHYLENE | NESTE OY (FI) | 1993-01-20 | — | — | EP | disclosed |
| EP-0327743-A1 | Procedure for manufacturing short-chain linear alpha- olefines from ethylene | NESTE OY (FI) | 1989-08-16 | — | — | EP | disclosed |
| EP-0327743-A1 | Procedure for manufacturing short-chain linear alpha- olefines from ethylene | NESTE OY (FI) | 1989-08-16 | — | — | EP | disclosed |
| US-4816610-A | CATALYTIC DIMERIZATION | NESTE OY (FI) | 1989-03-28 | — | — | US | disclosed |
| US-4296042-A | Preparation of unsaturated aliphatic insect pheromones using cyclic phosphonium ylids | SYNTEX (U.S.A.) INC. (US) | 1981-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340166-A1 | SELF-IMMOLATIVE SYSTEMS | MCL1, BCL3, BAP1 | TDP1 299/4885CYP3A4 1739/4885TSHR 1267/4885 |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | GRIA1, GRIA3, GRIA2 | TDP1 4606/4885CYP3A4 246/4885TSHR 1136/4885 |
| US-12110307-B2 | Self-immolative systems | MCL1, BCL3, BAP1 | TDP1 299/4885CYP3A4 1739/4885TSHR 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.